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RESEARCH
We report results of a case–control study of the associ-
ation between receipt of antimicrobial agents and diagnosis 
of community-acquired methicillin-resistant Staphylococcus 
aureus (MRSA) in the United Kingdom. Eligible adults, se-
lected from the General Practice Research Database, had 
no previous diagnosis of MRSA, no hospitalization in the 
past 2 years, and >2 years of follow-up recorded in the da-
tabase. For 2000–2004, we identiﬁ  ed 1,981 MRSA case-pa-
tients and 19,779 matched control-patients. The odds ratios 
(ORs) and 95% conﬁ  dence intervals (CIs) of MRSA diagno-
sis for patients who were prescribed 1, 2–3, or >4 antimicro-
bial drugs were 1.57 (CI 1.36–1.80), 2.46 (CI 2.15–2.83), 
and 6.24 (CI 5.43–7.17), respectively. Risk for community-
acquired MRSA increased with number of antimicrobial drug 
prescriptions, appeared to vary according to antimicrobial 
drug classes prescribed the previous year, and was highest 
for quinolones (OR 3.37, CI 2.80–4.09) and macrolides (OR 
2.50, CI 2.14–2.91).
M
ethicillin-resistant Staphylococcus aureus (MRSA) 
was detected in the United Kingdom in 1961, only 
months after methicillin introduction (1–3). Since then, 
MRSA has become a common cause of nosocomial infec-
tions worldwide (1–3). In 1993, MRSA infections emerg-
ing in the community were reported (1). MRSA infections 
acquired in the community differ from those acquired in the 
hospital with respect to their epidemiology and the charac-
teristics of the causative MRSA strains (1,2,4–6).
The prevalence of colonization with MRSA has been 
established in various community populations (7–9). How-
ever, patient characteristics and risk factors for clinically 
signiﬁ  cant MRSA infections acquired in the community 
have so far been described for speciﬁ  c outbreaks (10,11) or 
case series without an adequate population-based control 
group (12,13).
Nosocomial MRSA is associated with antimicrobial 
drugs and speciﬁ  c antimicrobial drug classes (14–16). The 
role of antimicrobial drugs in community-acquired MRSA 
is less clear. A recent study of 34 case-patients with com-
munity-acquired MRSA in Alaska showed that case-pa-
tients were more likely than control-patients to have re-
ceived antimicrobial agents in the year before the outbreak 
(10). Whether risk for community-acquired MRSA differs 
according to exposure to agents from different antimicrobi-
al drug classes is not clear. We therefore sought to describe 
the association between exposure to antimicrobial drugs 
and a subsequent diagnosis of MRSA, including exposure 
to individual antimicrobial drug classes.
Methods
We conducted our retrospective case–control study 
by using the General Practice Research Database (GPRD). 
This primary care database contains the diagnostic, labora-
tory test, and prescribing records of ≈3.2 million patients 
from >400 general practices in the United Kingdom. The 
GPRD is used extensively for research on drugs (17,18) 
and has also been used for research on infectious dis-
eases (19,20).
Case-Patients and Control-Patients
Eligible participants were >18 years of age, had no 
previous diagnosis of MRSA, no hospitalization in the past 
2 years, and >2 years of follow-up recorded in the GPRD. 
We excluded persons who had been recently hospitalized 
to ensure that we studied patients with community-acquired 
rather than community-onset MRSA.
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We identiﬁ  ed as case-patients all persons with a ﬁ  rst 
clinical diagnosis of MRSA from January 1, 2000, through 
December 31, 2004. To include all possible codes that a 
general practitioner could use to diagnose MRSA in the 
GPRD, we considered the following Read Clinical Clas-
siﬁ   cation codes (now National Health Service Clinical 
Terms) to represent a diagnosis of MRSA: 4JP..00 (methi-
cillin-resistant Staphylococcus aureus positive), SP25800 
(MRSA infection of postoperative wound), and ZV02A00 
([V]MRSA-multiple resistant Staphylococcus aureus in-
fection carrier). Because the most frequently entered code 
(4JP..00) does not explicitly differentiate between infection 
and colonization, we were unable to determine from the 
codes whether most patients in this study were infected or 
colonized. The date of the MRSA diagnosis was used as the 
index date for each case. Microbiologic test results were 
not used to identify case-patients with MRSA because re-
sults for such testing were not systematically available in 
the GPRD.
For each case-patient, we randomly selected 10 con-
trol-patients also from the GPRD, matched by general 
practice and age (±2 years). To control for calendar time, 
we assigned all control-patients their corresponding case-
patient’s index date. Control-patients had to fulﬁ  ll the same 
exclusion criteria as case-patients.
Exposure
For patients in each group, we determined exposure to 
antimicrobial drugs 30–365 days before the index date. To 
avoid the possibility of protopathic bias, we excluded anti-
microbial drug prescriptions made during the 29 days prior 
to the index date. We classiﬁ  ed the number of antimicrobial 
drugs prescribed for each patient during this period into 4 
categories: 0 (unexposed), 1, 2–3, and >4 prescriptions. For 
the same period, we deﬁ  ned 7 mutually exclusive categories 
for classes of antimicrobial drugs according to their British 
National Formulary (BNF) code (21): penicillins (5.1.1), 
cephalosporins (5.1.2), tetracyclines (5.1.3), macrolides 
(5.1.5), sulfonamides (5.1.8), quinolones (5.1.12), and an 
additional category of all other antimicrobial drugs. The 
“other antimicrobial drugs” category represented BNF an-
timicrobial drug categories that are infrequently prescribed 
(such as clindamycin) or for which the antimicrobial drug 
is part of a combination prescription listed in a nonantimi-
crobial drug BNF category.
Covariates
We adjusted for age, sex, smoking, and obesity (body 
mass index >30) as relevant demographic and life style fac-
tors possibly associated with exposure to antimicrobial drugs 
and MRSA infections. We further controlled for a series of 
known risk factors and concurrent conditions diagnosed dur-
ing the 2 years before the index date:  heart disease (myo-
cardial infarction, congestive heart failure), stroke, periph-
eral vascular disease, chronic obstructive pulmonary disease, 
liver disease, skin diseases (intertrigo, eczema, psoriasis), re-
nal failure, cancer, autoimmune diseases (lupus, rheumatoid 
arthritis), previous infection with Clostridium difﬁ  cile, and 
previous infection with S. aureus (susceptible to methicil-
lin). These conditions were deﬁ  ned according to diagnostic 
codes. We deﬁ  ned diabetes according to prescribed insulin 
or a clinical diagnosis in the 2 years before the index date. 
Finally, because of its immunosuppressive effect, we con-
sidered oral prednisone (deﬁ  ned according to prescriptions) 
prescribed during the 1 year before the index date to be a 
potentially confounding drug. 
Data Analysis
For each year of the study period, we calculated the 
incidence rate of ﬁ  rst MRSA diagnosis. The numerator 
consisted of the number of eligible case-patients each year; 
the denominator was all members of the GPRD population 
who were registered with general practices that met GPRD 
quality control standards and who were >18 years of age 
during that year.
We used conditional logistic regression to estimate the 
odds ratio (OR) of the association between antimicrobial 
drug prescriptions and a subsequent diagnosis of MRSA 
(22). For a rare outcome like MRSA, the OR is an approxi-
mation of the rate ratio. To obtain adjusted ORs, we repeat-
ed the analyses with covariates included in the regression 
model. In a separate analysis for the number of antimicro-
bial prescriptions, we included variables that represented 
the 4 categories we deﬁ  ned for the number of prescriptions. 
For our analysis of association according to different class 
of antimicrobial drug, we used a separate statistical model 
that contained variables for all 7 categories that represented 
the different classes of antimicrobial drugs.
In a sensitivity analysis of the 3 Read Clinical Classiﬁ  -
cation codes of our case deﬁ  nition, we determined the asso-
ciation between antimicrobial drugs and MRSA diagnosis 
in 3 different models. In each model, we included only the 
subset of case-patients who had the appropriate code and 
their corresponding control-patients. We also included the 
covariates in each of the 3 models to obtain adjusted ORs.
We used SAS version 9.1.3 (SAS Institute, Cary, NC, 
USA) for all analyses. We obtained approval from the Sci-
entiﬁ  c and Ethical Advisory Group of the GPRD and the 
McGill University Health Center Research Ethics Board at 
the Chest Hospital.
Results
A total of 3,408 patients had a ﬁ  rst diagnosis of MRSA 
in the GPRD during the study period. After exclusion of 
patients who did not ﬁ  t the other criteria, 1,981 (58.1%) 
remained eligible for our study, for which we identiﬁ  ed RESEARCH
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19,779 matching control-patients. The MRSA diagnosis 
was recorded as medical code 4JP..00 for 85.5%, code 
SP25800 for 8.8%, and code ZV02A00 for 5.7% of case-
patients.
During the study period, the annual number of case-
patients with MRSA in the GPRD-based population rose 
from 332 to 484 (Figure). Average incidence of MRSA in-
fections during the study period was 15.2 cases per 100,000 
persons per year. The median age of case-patients during 
the study period was 74 years (interquartile range 59–83 
years).
Overall, concurrent conditions were diagnosed more 
frequently for case-patients than for control-patients, and 
oral prednisone was prescribed more often for case-patients 
(Table 1). Smoking status did not differ signiﬁ  cantly (ad-
justed OR 1.06, 95% CI 0.95–1.17), but more case-patients 
than control-patients were recorded as obese (OR 1.27, 
95% CI 1.10–1.45). 
Exposure to any antimicrobial drug in the 30–365 days 
before index date, regardless of drug class and number of 
prescriptions, was associated with ≈3-fold risk of a MRSA 
diagnosis when compared with lack of such exposure (OR 
2.61, 95% CI 2.36–2.89, Table 2). Among case-patients, 
38.9% had not received any antimicrobial drug prescription 
during this period.
The association of antimicrobial drugs and MRSA was 
stronger for persons who had received more prescriptions 
of any class of antimicrobial drug (Table 2). A substantial 
proportion of case-patients (25.7%) had received >4 pre-
scriptions. This larger number of prescriptions was associ-
ated with a ≈6-fold increase in the risk for MRSA compared 
with the risk for persons who had not received any antimi-
crobial drug prescriptions (OR 6.24, 95% CI 5.43–7.17).
Individual classes of antimicrobial drugs were differ-
entially associated with a diagnosis of MRSA (Table 3). 
The association was strongest for macrolides and quino-
lones; adjusted ORs were 2.50 (95% CI 2.14–2.91) and 
Figure. Annual number of all study participants with methicillin-
resistant  Staphylococcus aureus (MRSA) recorded for the ﬁ  rst 
time in the General Practice Research Database (GPRD) and no 
hospitalization in the past 24 months (vertical bars). The annual 
incidence rate of MRSA per 100,000 adults in the GPRD is indicated 
by the line above the bars. Data from the GPRD, United Kingdom, 
2000–2004
Table 1. Characteristics of patients with (case-patients) and without (control-patients) a diagnosis of community-acquired methicillin-
resistant Staphylococcus aureus*
Characteristic
Case-patients
(N = 1,981), no. (%) 
Control-patients  
(N = 19,779), no. (%)  Crude OR 
Adjusted
OR† 95% CI 
Age, y (SD)  69.4 (18.4)  69.2 (18.5)  1.07 1.08 1.07–1.12‡
Male 864 (43.6)  8,429 (42.6)  1.05 1.08 0.98–1.20
Concurrent conditions 
 Diabetes  247  (12.5)  1,195  (6.0)  2.27 1.70 1.44–2.00‡
   MI and heart failure   117 (5.9)  563 (2.8)  2.22 1.42 1.13–1.80‡
   Stroke  95 (4.8)  212 (1.1)  4.64 4.09 3.13–5.35‡
   Peripheral vascular disease   49 2.5)  92 (0.5)  5.49 3.65 2.49–5.35‡
   COPD  117 (5.9)  465 (2.4)  2.68 1.45 1.13–1.85‡
  Skin diseases (intertrigo, 
 eczema,  psoriasis) 
196 (9.9)  1,332 (6.7)  1.53 1.19 1.01–1.41‡
   Renal failure  65 (3.3)  188 (1.0)  3.64 2.53 1.88–3.50‡
   Cancer   42 (2.1)  183 (0.9)  2.39 2.01 1.39–2.91‡
   Liver disease  6 (0.3)  8 (0.04)  7.50 6.69 2.17–20.66‡
   Autoimmune diseases  17 (0.9)  93 (0.5)  1.84 1.27 0.72–2.25
Clostridium difficile 9 (0.5)  15 (0.1)  6.20 5.33 2.13–13.35‡
S. aureus susceptible to
 methicillin 
8 (0.4)  14 (0.1)  5.71 2.98 1.13–7.83‡
Oral prednisone use  216 (10.9)  1,163 (5.9)  1.99 1.11 0.93–1.33
Lifestyle factors 
  Smoking   718 (36.2)  6,365  32.2)  1.21 1.06 0.95–1.17
   Obesity  323 (16.3)  2,253 (11.4)  1.54 1.27 1.10–1.47‡
*Data from the General Practice Research Database, United Kingdom, 2000–2004. OR, odds ratio; CI, confidence interval; MI, myocardial infarction; 
COPD, chronic obstructive pulmonary disease. 
†Adjusted for all other variables in the table and exposure to antimicrobial drugs in the 30–365 days period before the index date. 
‡p<0.05. Antimicrobial Drugs and Community-acquired MRSA
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3.37 (95% CI 2.80–4.09), respectively. This association 
means that risk for an MRSA diagnosis triples for persons 
who received >1 prescription of a quinolone, regardless of 
how many other antimicrobial drugs were prescribed for 
this patient during the 30–365 days before the diagnosis. 
We could not establish an association between tetracycline 
prescriptions and MRSA in our study.
The results of our sensitivity analysis for diagnostic 
codes are presented in Table 4. Despite some variation in 
the estimated OR between the different methods of coding 
the MRSA diagnosis, we found an association with anti-
microbial drugs, regardless of the code used to record the 
MRSA diagnosis.
Discussion 
This study provides evidence of an association between 
previous antimicrobial drug prescriptions and a diagnosis 
of MRSA in the community. This association appears to 
be dose-dependent and to vary according to antimicrobial 
class; it is particularly strong for previous exposure to ﬂ  uo-
roquinolones and macrolides. A substantial proportion of 
case-patients, however, were not prescribed antimicrobial 
drugs in the year before MRSA diagnosis. Persons who had 
concurrent conditions and persons who were obese were at 
higher risk for MRSA.
The clear dose-response relationship and the differen-
tial associations across antimicrobial drug classes support 
an association of antimicrobial drugs and MRSA in the 
community. This association is consistent with nosocomial 
MRSA, in which the use of speciﬁ  c antimicrobial drugs is 
linked to antimicrobial resistance. Previous studies have 
found ﬂ  uoroquinolones, macrolides, and cephalosporins to 
be associated with nosocomial MRSA (14–16,23). More-
over, a dose-dependent association exists between expo-
sure to antimicrobial drugs and nosocomial MRSA on the 
patient level and on the hospital level (16).
In a US surveillance study, incidence of community-
acquired MRSA was 25.7 case-patients per 100,000 in At-
lanta and 18.0 case-patients per 100,000 in Baltimore, ﬁ  nd-
ings that are highly consistent with ours (12). In that study, 
a considerable proportion of cases occurred in persons >65 
years of age. In our study, compared with previous out-
break reports (10,11), case-patients were older and had 
more concurrent conditions. This ﬁ  nding is likely because 
we did not include any cases in children and, in contrast to 
reports of outbreaks, our cases are sporadic and thus less 
prone to be reported.
Similarly, speciﬁ  c occupation-related risk factors (e.g., 
abrasions, crowded housing) are likely to be more preva-
lent in a study based on military beneﬁ  ciaries compared 
with a study based on the general population. This could 
explain the higher incidence of MRSA infections found in 
such a study (13) than in ours.
Our study population was a representative sample of the 
UK general population (17). The use of the GPRD therefore 
enables the examination of a large number of MRSA infec-
tions diagnosed by general practitioners in the community. 
However, the GPRD has some limitations for the study of 
Table 2. Risk for infection with community-acquired methicillin-resistant Staphylococcus aureus (MRSA)* 
No. prescriptions of 
antimicrobial drugs 
Case-patients
(N = 1,981), no. (%) 
Control-patients 
(N = 19,779), no. (%)  Crude OR 
Adjusted
OR† 95% CI 
0 (reference)  770 (38.9)  12,821 (64.8)  1 1
>1 1,211 (61.1)  6,958 (35.2)  2.98 2.61 2.36–2.89
   1  328 (16.6)  3,306 (16.7)  1.69 1.57 1.36–1.80
   2 or 3  373 (18.8)  2,389 (12.1)  2.73 2.46 2.15–2.83
>4 510 (25.7)  1,263 (6.4)  7.27 6.24 5.43–7.17
*For persons prescribed <1 antimicrobial drug in the 30–365 days before their index date, relative to risk for MRSA infection in persons with no 
prescriptions during the same period. Data from General Practice Research Database, United Kingdom, 2000–2004. OR, odds ratio; CI, confidence 
interval. 
†Adjusted for all variables in Table 1. 
Table 3. Risk for infection with community-acquired methicillin-resistant Staphylococcus aureus (MRSA)* 
Class of antimicrobial drug 
Case-patients
(N = 1,981), no. (%) 
Control-patients  
(N = 19,779), no. (%)  Crude OR 
Adjusted
OR† 95% CI 
No prescription (reference 
group)
770 (38.9)  12,821 (64.8)  1 1
Cephalosporins   27 13.6 ()  994 (5.0)  2.01 1.85 1.57–2.19
Macrolides 32 (16.2)  1,04 (5.2)  2.70 2.50 2.14–2.91
Penicillins 540 (27.3)  3,104 (15.7)  1.67 1.56 1.39–1.76
Other antimicrobial drugs   204 (10.3)  1,615 (8.1)  2.02 1.90 1.61–2.24
Sulfonamides 260 (13.1)  1,114 (5.8)  1.77 1.74 1.48–2.04
Tetracyclines   77 (3.9)  461 (2.3)  1.14 1.09 0.83–1.43
Quinolones 218 (11.0)  434 (2.2)  3.81 3.37 2.80–4.09
*For persons prescribed different classes of antimicrobial drugs in the 30–365 days before their index date, relative to risk for MRSA infection in persons 
with no prescriptions during the same period. Data from General Practice Research Database, United Kingdom, 2000–2004. OR, odds ratio; CI, 
confidence interval. 
†Adjusted for prescriptions from other antimicrobial drug classes in the 30–365 days period before the index date and all variables in Table 1. RESEARCH
998  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 7, July 2007
an infectious disease. We lacked information on severity 
and site of MRSA infection and on patient lifestyle char-
acteristics (e.g., incarceration, intravenous drug use). We 
also lacked information on molecular characteristics of the 
MRSA strains and thus cannot exclude the possibility that 
MRSA was diagnosed in cases that did not result from be-
tween-patient spread within the community, but rather from 
secondary exposure to the hospital environment through 
family members, visitation, or employment. However, the 
importance of the lack of microbiologic information on the 
causative MRSA strains may be questioned because it no 
longer enables a distinction to be made between commu-
nity and nosocomial MRSA strains (24).
The clinical codes that we used for our case deﬁ  nition 
are likely to be speciﬁ  c, but they may lack sensitivity; some 
MRSA infections that would have met the Centers for Dis-
ease Control and Prevention’s case deﬁ  nition of infection 
may not be captured with the clinical codes. This lack of 
sensitivity may affect risk factors for MRSA that we ob-
served in this study as well as the strength of the association 
between antimicrobial drugs and later MRSA diagnosis.
To our knowledge, MRSA infections in the GPRD 
have not been previously studied, although infectious dis-
eases in this database have been, such as acute respiratory 
infections (19), urinary tract infections (20), C. difﬁ  cile 
infections (25), pneumonia (26), and sexually transmitted 
infections (27). Disease codes for clinically relevant out-
comes in the GPRD have been validated (17); however, 
MRSA has not been included in such studies.
In previous UK community studies, ≈0.8% of elderly 
participants were colonized with MRSA (9,28). In a meta-
analysis, the pooled MRSA colonization rate was 1.3% (8). 
In persons without prior health care contacts, the rate was 
0.2% (8). We report an incidence rate of MRSA diagnosis 
in the community that is too low to be consistent with these 
prevalence ﬁ  gures, probably because general practitioners 
are unlikely to screen asymptomatic patients for coloniza-
tion with MRSA.
The results of our sensitivity analysis of the 3 diag-
nostic codes we used to deﬁ  ne these MRSA cases suggest 
that antimicrobial drugs promote both MRSA infection and 
colonization. The association between antimicrobial drugs 
and MRSA diagnosis was weaker in case-patients with 
a diagnosis of carrier status and stronger in those with a 
postoperative wound infection. The association observed 
in the patients who had their diagnosis recorded with the 
most frequently used code (4JP..00) appeared to be more 
similar to those coded as postoperative wound infections 
(SP25800) than to those coded as carriers (ZV02A00). This 
ﬁ  nding supports the hypothesis that active infections are 
more likely than colonization to be recorded in a general 
practice database. Therefore, separating risk factors for ac-
quiring MRSA from risk factors for increased severity of 
infection with MRSA using the approach of this study may 
be difﬁ  cult.
We did not consider antimicrobial drugs that were pre-
scribed in the 30 days before MRSA diagnosis. With this 
exposure deﬁ  nition, we prevent mistaking prescriptions is-
sued for treatment of the infection as causes of the infec-
tion (protopathic bias [29]). This distinction is relevant for 
MRSA, for which the diagnosis is likely delayed due to 
outstanding microbiologic test results or likely made after 
failure of empirical treatment with antimicrobial drugs. 
Therefore, we may have wrongly classiﬁ  ed as unexposed 
some persons whose exposure to antimicrobial drugs in 
fact preceded the MRSA infection. Any bias resulting from 
this exposure deﬁ  nition will be toward the null hypothesis 
and thus will weaken the effect of antimicrobial drugs as 
promoters of MRSA infections.
To minimize the chances of overlooking any important 
confounders, we adjusted our analyses for age, sex, life-
style factors, and a broad range of concurrent conditions. 
That antimicrobial drug prescriptions are a marker for an 
important unknown confounder is remotely possible. How-
ever, to substantially bias our results, such a confounder 
would need to be strongly related to both the prescription 
of antimicrobial drugs and the diagnosis of MRSA but un-
related to our study covariates.
Further support for our results comes from the eco-
logic association between ﬂ  uoroquinolone use and nos-
ocomial MRSA found in an intervention study (30) and 
a quasi-experimental study (31). Similar to nosocomial 
MRSA (16,23), the use of speciﬁ  c antimicrobial drugs in 
the community may cause selection pressures that favor 
Table 4. Sensitivity analysis for the clinical code used to define methicillin-resistant Staphylococcus aureus (MRSA)* 
Case-patients Control-patients 
Clinical code†   N (%)  % Exposed  N % Exposed  Crude OR  Adjusted OR‡  95% CI 
Any code  1,981 (100)  61.1 19,779 35.2 2.98 2.61 2.36–2.89
4JP..00 1,735 (85.5)  62.2 17,327 35.7 3.05 2.66 2.39–2.97
SP25800 157 (8.8)  60.5 1,570 32.7 3.34 2.99 2.06–4.33
ZV02A00 113 (5.7)  47.8 1,122 30.5 2.09 1.98 1.30–3.01
*Risk for MRSA diagnosed in the community for persons with any number of antimicrobial drug prescriptions (exposed) in the 30–365 days before their 
index date relative to risk for MRSA for persons with no prescriptions during the same period. Data from 4 different analyses of a matched case-control 
study of patients listed in the General Practice Research Database, UK, 2000–2004. OR, odds ratio; CI, confidence interval. 
†4JP..00, MRSA positive; SP25800, MRSA infection of postoperative wound; ZV02A00, [V]MRSA multiple-resistant Staphylococcus aureus infection 
carrier. 
‡Adjusted for all covariates in Table 1. Antimicrobial Drugs and Community-acquired MRSA
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the acquisition of resistance in S. aureus on the commu-
nity level.
In conclusion, the role of antimicrobial drugs in 
MRSA diagnosed in the community appears to be similar 
to their role in nosocomial MRSA. Therefore, appropriate 
use of antimicrobial drugs, in addition to traditional infec-
tion control measures, may be a strategy to not only control 
nosocomial MRSA (32), but also to limit the incidence of 
community-diagnosed MRSA infections.
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